Accueil   Diary - News   All news PX’Therapeutics and RELIEF THERAPEUTICS Holding AG announce a strategic collaboration agreement for the recombinant production of atexakin alfa

PX’Therapeutics and RELIEF THERAPEUTICS Holding AG announce a strategic collaboration agreement for the recombinant production of atexakin alfa

LOGO_PXT-2011_large
 
PX’Therapeutics, a subsidiary of the Aguettant group, a company that specializes in the customer-tailored development of recombinant proteins, and RELIEF THERAPEUTICS Holding AG (“Relief”,SIX:RLF), a biotechnology company dedicated to the clinical development of innovative molecules for the treatment of certain diabetes-related complications, respiratory disorders and rare diseases, have announced today a strategic collaboration agreement for the production of atexakin alfa, a low-dose formulation of the recombinant human protein interleukin 6.
 
 
 
 
Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree